Urinary tract infections (UTIs) are the second most common type of infections requiring antibiotics, with Enterobacterales being the most common agents of infection.1 Due to the extensive use of broad-spectrum antibiotics, the prevalence of multidrug-resistant Enterobacterales has increased in the community, which makes therapeutic choices a great challenge.
Pivmecillinam (orally active prodrug of mecillinam) is one of the first-line drugs recommended for the treatment of uncomplicated UTIs in the European clinical practice guidelines due to its selective activity against gram-negative bacteria, its pharmacokinetic properties with high drug concentration in urine, and its low community resistance rate.2-4

Clique aqui para aceder ao artigo completo (apenas em inglês)